Antihypertensive activity of KR-31081, an orally active nonpeptide AT1 receptor antagonist / Sunghou Lee 1
Abstract 1
요약 1
1. Introduction 1
2. Materials and Methods 2
3. Results 3
4. Discussion 5
Acknowledgement 6
References 6
[저자소개] 7
초록보기
The pharmacological profile of KR-31081, a newly synthesized AT1 receptor antagonist, was evaluated in pithed rats, conscious renal hypertensive rats (RHRs) and conscious furosemide-treated beagle dogs. In pithed rats, KR-31081 (i.v.) induced a non-parallel right shift in the dose-pressor response curve to angiotensin II (ID50: 0.05 mg/kg) with a dose-dependent reduction in the maximum responses; this antagonistic effect was about 40 times more potent than losartan (ID50: 1.74 mg/kg) which showed competitive antagonism. KR-31081 did not alter the responses induced by other agonists such as norepinephrine and vasopressin. In RHRs, orally given KR-31081 produced a dose-dependent and long-lasting (>24 h) antihypertensive effect with a higher potency to losartan (ED20: 0.30 and 3.36 mg/kg, respectively). In furosemide-treated dogs, orally given KR-31081 produced a dose-dependent and long-lasting (>8h) antihypertensive effect with a rapid onset of action (time to Emax: 1-1.5 h) and 20-fold greater potency than losartan (ED20: 0.41 and 8.13 mg/kg, respectively). These results suggest that KR-31081 is a potent, orally active AT1 receptor antagonist useful for the research and diagnostic tools as an added exploratory potential.
비펩타이드성 안지오텐신 수용체 길항제로 새롭게 개발된 KR-31081에 대한 생체 내 활성을 세가지 동물모델에서 검증하였다. 척수장애 동물모델에서 KR-31081은 로사탄보다 40배 이상의 경쟁적인 혈압강하 효과를 나타내었으며, 신성고혈압쥐 모델에서 KR-31081은 로사탄보다 10배 가량의 지속형 효과를 나타내었다. 또한 개실험에서 구강 투여한 KR-31081은 로사탄보다 20배 이상의 지속적인 혈압강하 효과를 나타내었다. 실험에 사용된 동물 모델 시스템에서 다른 혈관조절물질들과 상호작용을 하지 않는 것으로 나타난 KR-31081은 향후 고혈압 및 혈관질환에 대한 연구 및 진단에 활용될 수 있을 것이라고 판단된다.
Angiotensin II receptors and angiotensin II receptor antagonists.
미소장
2
Advances in Pharmacology
미소장
3
Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.
미소장
4
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
미소장
5
Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs
미소장
6
In vivo pharmacology of DuP 753.
미소장
7
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
미소장
8
Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
미소장
9
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
미소장
10
A novel radioligand for imaging the AT 1 angiotensin receptor with PET
미소장
11
Positron-Emission Tomography Imaging of the Angiotensin II Subtype 1 Receptor in Swine Renal Artery Stenosis
미소장
12
PET Imaging of the AT 1 receptor with [ 11C]KR31173
미소장
13
A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat.
미소장
14
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist
미소장
15
Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.
미소장
16
Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.
미소장
17
Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
미소장
18
Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
미소장
19
Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.